Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Stojakovic, T; Claudel, T; Putz-Bankuti, C; Fauler, G; Scharnagl, H; Wagner, M; Sourij, H; Stauber, RE; Winkler, K; März, W; Wascher, TC; Trauner, M.
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
Atherosclerosis. 2010; 209(1): 178-183.
Web of Science PubMed FullText FullText_MUG Google Scholar


Autor/innen der Med Uni Graz:
Claudel Thierry
Fauler Günter
Maerz Winfried
Putz-Bankuti Csilla
Scharnagl Hubert
Sourij Harald
Stauber Rudolf
Stojakovic Tatjana
Trauner Michael
Wagner Martin
Wascher Thomas

Dimensions Citations:

Plum Analytics:
Objective: Primary biliary cirrhosis (PBC) is frequently associated with hypercholesterolemia and with an increased cardiovascular morbidity and mortality. Statins lower serum cholesterol levels and may thus improve the cardiovascular risk in PBC patients. The aim of our study was to prospectively examine the efficacy of low-dose atorvastatin on cholestasis as well as cardiovascular risk markers such as dyslipidemia and vascular function in patients with PBC. Methods: Nineteen patients with early-stage (biopsy proven and AMA positive) PBC and low-density lipoprotein cholesterol (LDL-C) above 130 mg/dL were included in this single-center study and treated with atorvastatin 10 mg per day for one year. Results: Concentrations of total cholesterol, LDL-C, LDL triglycerides, oxLDL, IgG and sVCAM-1 decreased significantly after 48 weeks of atorvastatin treatment. Flow-mediated dilation (FMD) of the brachial artery as an indicator of vascular function significantly increased, while carotid artery intima-media thickness and vascular wall stiffness did not progress under treatment. No statistical differences in liver enzymes were observed except a transient increase of alkaline phosphatase. Conclusion: Treatment with low-dose atorvastatin is safe in early-stage PBC, effectively reduces total cholesterol, LDL-C, LDL triglycerides, oxLDL and sVCAM-1 and improves vascular function as reflected by FMD, without affecting cholestasis progression. Therefore, statin therapy should be considered in PBC patients with additional risk factors for cardiovascular disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Blood Vessels - drug effects Blood Vessels - physiopathology
Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention and control
Cholestasis - etiology Cholestasis - physiopathology
Cholesterol - blood
Female -
Heptanoic Acids - administration and dosage
Humans -
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration and dosage
Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Hypercholesterolemia - etiology
Liver Cirrhosis, Biliary - complications Liver Cirrhosis, Biliary - physiopathology
Male -
Middle Aged -
Prospective Studies -
Pyrroles - administration and dosage

Find related publications in this database (Keywords)
Primary biliary cirrhosis
Vascular function
© Meduni Graz Impressum